One local man fighting his toughest fight to beat Renal Clear Cell Carcinoma kidney cancer
AUGUSTA, Ga. (WJBF)- The average age for someone diagnosed with Kidney Cancer in the U.S. is 65. But one local man's decades-long battle with cancer began before he was even 10 years old.
Doctors tell me Casey Rivers' story is unique.
'You would not expect that type of kidney cancer in a child. There are other kidney cancers that you might see more commonly in a child, but yeah, most commonly in adults.' Doctors Hospital Radiation Oncologist Dr. John Stewart said.
'I was about nine– it was the summer of 2002, I think. I was having a lot of constipation, just wasn't feeling well, and I think me and my mom probably went to the ER for like months before we actually got an answer…' Casey Rivers said.
An answer that would change Rivers' life.
'We actually got an answer from a pediatric doctor, and he was like, he saw a mass on my liver, and it was dead in the center…' Rivers said.
Since his diagnosis with Renal Clear Cell Carcinoma, Rivers has had a liver transplant and a kidney removal. But his biggest challenges aren't physical, they're financial.
'If I don't have a job that offers it, I can't go apply for it because as soon as I fill out, I had cancer, or currently have it, they deny it…'
Rivers says he's at a point where it costs to live.
'If I don't go to work, I don't make it– that's just point blank period. I have to get up and go to work because there's no way I can apply for anything, who's gonna accept me.'
Dr. Stewart says some cases can be prevented with early detection.
'Stick to the US preventative Task Force Guideline for screening for common cancer such as breast cancer, colon cancer, prostate cancer. Rare cancers, unfortunately don't have great screening tests, so family history is very important for a lot of rare cancer…'
'I know people get so excited when we ring that bell– that's the common thing– and I don't think the patients are that excited we know the journey is really about to start,' Rivers said.
If you are interested in donating and helping Rivers and his family, a GoFundMe can be found here.
Saturday, April 2nd, A motorcycle 'Ride for Rivers' will take place, followed by a fundraising event in Denmark, South Carolina.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
13 minutes ago
- Associated Press
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
WILMINGTON, Del., June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals', 'NRx' or the 'Company'), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ('HOPE,' or the 'Company'), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16–17, 2025. Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE, will deliver a corporate presentation highlighting the company's latest advances. The presentation will be available on demand to registered attendees beginning at 7:00 a.m. Eastern Time on Monday, June 16, 2025. In addition, the company will be participating in one-on-one meetings with investors throughout the conference. Please request 1:1 meetings on the HCW conference website listed below. Event Details: About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy, for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as a treatment for complicated UTI. NRx recently filed an Abbreviated New Drug Application (ANDA) for NRX-100 (preservative free IV ketamine) for use in ketamine's currently approved indications. Additionally, the Company has initiated a New Drug Application filing for NRX-100 for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office. About HOPE Therapeutics, Inc. HOPE Therapeutics, Inc. ( ), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'believe,' 'intend,' 'look forward,' and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, whether the USPTO approves the Company's patent, and whether the FDA will approve the Company's NDA. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc.
Yahoo
27 minutes ago
- Yahoo
Werewolf Therapeutics to Participate in the BIO International Convention
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the 'Company' or 'Werewolf') (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will participate in a panel discussion at the upcoming BIO International Convention taking place June 16-19 in Boston, Massachusetts. The panel will focus on how conditionally activated biologics, including those being developed by Werewolf, represent a new generation of immune therapies designed to maximize anti-tumor activity while minimizing systemic toxicity. These self-regulating therapies hold the potential to redefine treatment paradigms in oncology and beyond. Panel details: Topic: Beyond Bispecifics and ADCs: Conditionally Active BiologicsDate: Wednesday, June 18, 2025Time: 10:15am ETLocation: 206AB The panel coincides with the launch of Werewolf's 'Full Moon Moment,' an awareness initiative supporting its ongoing national clinical trials, including one evaluating WTX-124, our IL-2 INDUKINE molecule, in which multiple responses have been reported, including a patient with cutaneous squamous cell carcinoma who has been in remission for more than a year. The campaign aims to highlight the potential for such outcomes and inspire patients to explore treatment options that could open a new chapter in their journey. The 'Full Moon Moment' embodies how Werewolf's INDUKINE™ molecules are designed to awaken their potent tumor-killing power upon entering the tumor microenvironment. Learn more about Werewolf's current WTX-124 clinical trial here. About Werewolf Therapeutics:Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf's INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company's most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf's strategy, future operations, prospects, plans, and objectives of management; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; and the anticipated safety profile of product candidates constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'aim,' 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'designed to,' 'engineered,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'positioning itself to,' 'potential,' 'predict,' 'project,' 'promise,' 'should,' 'target,' 'will,' 'working to,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, and the initiation and completion of preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the future results of the trial and future clinical trials; as well as the risks and uncertainties identified in the 'Risk Factors' section of the Company's most recent Form 10-Q filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved. Investor ContactDan FerryLifeSci Advisors617.430.7576daniel@ Media Contact:Amanda SellersDeerfield Company Contact:Timothy TrostChief Financial OfficerWerewolf Therapeuticsttrost@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Carolina Hills Classic Bike Tour starts Thursday in Gvl to fight Arthritis
Greenville, S.C. (WSPA)- It's a cycling tour through the Blue Ridge Mountains to raise money for the Arthritis foundation. In the Carolina Hills Classic cyclists are set to start riding North just before 8:30 Thursday morning. It's a new 250 mile cycling tour Blue Ridge Mountain foothills. This ride will take four days, and cyclists will be supported with refuel stops along the way. It will start and end in Greenville and cyclists will have stops in North Carolina along the way, ending at Southernside Brewing Co The ride is projected to raise more than $250,000 and it's inaugural year for arthritis research according to organizers Approximately 60 million U.S. adults live and thrive with arthritis. It is the No. 1 cause of disability in the U.S. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
